Incivek's Sales Expectations Are up After Strong Launch
By Tom Wall
Monday, August 1, 2011
For those to whom much is given, much is expected. So it is with Vertex Pharmaceutical Inc. as several analysts upped their sales estimates for just-launched hepatitis C treatment Incivek (telaprevir) after the company reported second quarter sales of about $75 million more than doubling previous Street estimates and more than tripling second quarter sales of $21 million for Merck & Co. Inc.'s competing Victrelis (boceprevir).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.